- Conditions
- Chronic Kidney Disease
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 2,682,052 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Minneota, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1105–1128
of 1,904
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lung Cancer, Non-small Cell Carcinoma
- Interventions
- Induction Durvalumab, Chemotherapy, Radiation, Consolidation durvalumab
- Drug · Radiation
- Lead sponsor
- Rachel Sanborn
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Wichita, Kansas • Minneapolis, Minnesota + 2 more
- Conditions
- Hyperkalaemia, Metabolic Acidosis, Chronic Kidney Disease
- Interventions
- Sodium zirconium cyclosilicate, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 29
- States / cities
- Florence, Alabama • Chula Vista, California • Downey, California + 25 more
- Conditions
- Non Hodgkin Lymphoma
- Interventions
- acalabrutinib, rituximab (IV), Lenalidomide
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2028
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Downey, California • Duarte, California + 18 more
- Conditions
- Type 2 Diabetes
- Interventions
- exenatide once weekly, basal insulin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 7,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Germ Cell Tumor, Nonseminomatous Germ Cell Tumor, Seminoma, Germinomatous Germ Cell Tumor, Dysgerminoma, Pineal Germ Cell Tumor
- Interventions
- Durvalumab, Tremelimumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- Cisplatin, Carboplatin, Etoposide, Durvalumab, Ceralasertib
- Drug
- Lead sponsor
- Muhammad Furqan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more
- Conditions
- Bladder Cancer
- Interventions
- Docetaxel, ZD1839, Dexamethasone
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Healthy
- Interventions
- FosD, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 20 Years to 45 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Chronic Kidney Disease
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 4,304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Hawaiian Gardens, California • Lomita, California + 46 more
- Conditions
- COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease
- Interventions
- EVUSHELD
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 4,724 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Children and Adolescent With Type 2 Diabetes
- Interventions
- Exenatide Once Weekly, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 16
- States / cities
- Los Angeles, California • New Haven, Connecticut • Iowa City, Iowa + 13 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- San Diego, California • Baton Rouge, Louisiana • Philadelphia, Pennsylvania
- Conditions
- Hypertension
- Interventions
- Metformin, CIN-107
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- GALIDA
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 580 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Columbiana, Alabama • Mobile, Alabama + 61 more
- Conditions
- Neoplasms, Squamous Cell
- Interventions
- Gefitinib (Iressa), cisplatin, radiotherapy
- Drug · Radiation
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Dallas, Texas
- Conditions
- Diabetic Kidney Disease
- Interventions
- MEDI3506, Placebo, Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 42 more
- Conditions
- Colorectal Neoplasms, Metastases, Neoplasm
- Interventions
- ZD6126, Placebo, 5-fluorouracil, leucovorin, oxaliplatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Chicago, Illinois + 7 more
- Conditions
- Healthy
- Interventions
- AZD9742, Placebo to match AZD9742
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 23 Years to 45 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Cardiovascular Disease
- Interventions
- ticagrelor, prasugrel, Placebo
- Drug
- Lead sponsor
- Yochai Birnbaum
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Houston, Texas
- Conditions
- Mantle Cell Lymphoma (MCL)
- Interventions
- Acalabrutinib, Venetoclax, Rituximab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 5
- States / cities
- Hackensack, New Jersey • Stony Brook, New York • Cleveland, Ohio + 2 more
- Conditions
- Major Depressive Disorder
- Interventions
- AZD6765, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 27
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Orange, California + 24 more
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- Not listed
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2028
- U.S. locations
- 8
- States / cities
- San Diego, California • Denver, Colorado • Boston, Massachusetts + 5 more
- Conditions
- Healthy
- Interventions
- Lanabecestat, Simvastatin, Midazolam, Donepezil
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 2
- States / cities
- Daytona Beach, Florida • Dallas, Texas